Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
Phase I/II Trial Of Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab (Avastin) for Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma.
Sponsor: Feinstein Institute for Medical Research
A PHASE1/PHASE2 clinical study on Anaplastic Astrocytoma and Glioblastoma Multiforme, this trial is actively recruiting participants. The trial is conducted by Feinstein Institute for Medical Research and has accumulated 12 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
12 versions recorded-
May 2025 — Present [monthly]
Recruiting PHASE1/PHASE2
-
Sep 2024 — May 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Feb 2024 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2022 — Feb 2024 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 7 earlier versions
-
Nov 2021 — Dec 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — Nov 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2019 — Oct 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — Jun 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Oct 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Feinstein Institute for Medical Research
- Northwell Health
For direct contact, visit the study record on ClinicalTrials.gov .